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Abstract  
The impetus for discovery and evaluation of protein biomarkers has been accelerated by 
recent development of advanced technologies for rapid and broad proteome analyses. Mass 
spectrometry (MS)-based protein assays hold great potential for in vitro biomarker studies. 
Described here is the development of a multiplex Mass Spectrometric Immunoassay (MSIA) for 
quantification of apolipoprotein C-I (apoC-I), apolipoprotein C-II (apoC-II), apolipoprotein C-III 
(apoC-III) and their proteoforms. The multiplex MSIA assay was fast (~40 min) and high-
throughput (96 samples at a time). The assay was applied to a small cohort of human plasma 
samples, revealing the existence of multiple proteoforms for each apolipoprotein C. The 
quantitative aspect of the assay enabled determination of the concentration for each proteoform 
individually. Low-abundance proteoforms, such as fucosylated apoC-III, were detected in less 
than 20% of the samples. The distribution of apoC-III proteoforms varied among samples with 
similar total apoC-III concentrations. The multiplex analysis of the three apolipoproteins C and 
their proteoforms using quantitative MSIA represents a significant step forward toward better 
understanding of their physiological roles in health and disease. 
 
Keywords: apolipoprotein C-I, C-II, C-III, proteoforms, biomarkers, mass spectrometric 
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1. Introduction 
As a result of alternative splicing, single-nucleotide polymorphisms (SNPs), and 
posttranslational modifications (PTMs), proteins can exist as multiple variants (or “proteoforms” 
- [1]) in vivo. These proteoforms may play important physiological roles, with possible 
implications in disease development. Thus, development of methods for detection and 
quantification of proteoforms is considered an important, albeit challenging task.  
Mass spectrometry (MS)-based protein assays hold great potential for in vitro detection 
of protein biomarkers. Intrinsic to the MS-based methods is the measurement of molecular mass 
– a unique property of each protein.  Several MS-based methodologies employ a combination of 
immuoaffinity enrichment and MS detection. Among them are MSIA [2, 3], SELDI [4], 
SISCAPA [5, 6], iMALDI [7] and SILAC [8]. Some of these methods are geared towards 
detection of proteolytic peptides as surrogate measures for protein quantification (e.g., 
SISCAPA, SILAC), leaving a large part of the protein sequence un-assessed. Hence, those 
approaches cannot detect proteoforms without a priori knowledge of their existence. Top-down 
MS-based approaches are better suited for proteoforms detection because they detect the mass of 
the intact proteins, thus covering putative modifications in the entire protein sequence [9, 10]. 
The mass spectrometric immunoassay (MSIA) is one such top-down proteomics method 
[2, 3, 11-14]. MSIA combines micro-scale immunoaffinity separation with mass spectrometric 
detection. Antibodies towards targeted proteins are attached to porous microcolumns fitted at the 
entrance of a pipette tip, and used for proteins affinity extraction directly from the biological 
sample. After the affinity capture, proteins are eluted either directly onto a target plate for 
MALDI-TOF MS analysis [15], or eluted with a small volume of elution solution for subsequent 
LC-ESI MS analysis [16]. When optimized, MSIA can provide detailed insights into the intrinsic 
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protein properties, in both qualitative and quantitative manner [17-21]. The capability for 
multiplexing is another advantage of MSIA, because it enables simultaneous determination of 
several proteins in a single analysis [22, 23]. In relative quantification mode, the multiplex MSIA 
approach yields a protein profile consisting of all proteoforms, which can be used to assess the 
protein function. In fully quantitative mode (using internal reference standards), multiplex MSIA 
provides information about the concentration of the native (intact) protein and the various 
proteoforms that may exist alongside.  
Apolipoprotein C-I (apoC-I), apolipoprotein C-II (apoC-II) and apolipoprotein C-III 
(apoC-III) are members of the same apolipoprotein family, and are synthesized in the liver. They 
are carried primarily in the very-low density lipoprotein (VLDL) fraction [24] although they 
become associated with other lipoproteins during normal lipid metabolism. They play important 
roles as co-factors and inhibitors in triglyceride metabolism. For example, apoC-II is required for 
efficient lipolysis of triglyceride (TG)-rich lipoproteins through lipoprotein lipase activation 
[25]. In contrast, apoC-III inhibits the lipolysis of TG-rich lipoproteins and is associated with 
elevated TG-rich lipoproteins and possibly CVD [26]. Interest in apoCs, particularly apoC-III, 
has grown considerably since recent studies indicate loss-of-function mutations in the apoC-III 
gene are associated with reduced triglyceride levels and cardiovascular risk [27-29]. In fact, there 
is intensive new drug development targeting apoC-III levels [30, 31]. Importantly, several 
proteoforms of apoCs exist [32] which reflect their function in vivo. MS-based methods provide 
a unique opportunity to study apoCs proteoforms [33-37], and correlate their structural 
modifications with function in physiological and pathological states.  
Presented here is the development and application of a multiplex MSIA for detection and 
quantification of apoC-I, apoC-II, and apoC-III and their proteoforms. The main scope was to 
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investigate the quantitative distribution and the heterogeneity of the apoCs in human plasma, and 
to provide insight into the potential role of these proteoforms as biomarkers. 
2. Material and methods 
2.1. Reagents  
Polyclonal goat anti-human antibodies to apoC-I (Cat. No. 31A-G1b), apoC-II (32A-
G2b), apoC-III (33A-G2b), and ultra-pure human apolipoprotein C-I (31P-UP201) were obtained 
from Academy Bio-medical Co. (Houston, TX, USA). Native human apoC-II (Cat. No. MD-26-
0012P), native human apoC-III (MD-26-0013P), and mouse anti-hen egg lysozyme (128-10094) 
were obtained from RayBiotech (Norcross, GA, USA). Protein calibration standard I (Cat. No. 
206355) was purchased from Bruker (Billerica, MA). Phosphate buffered saline (PBS) buffer 
(Cat. No. 28372), MES buffered saline (28390), acetonitrile solution (ACN; A955-4), 
hydrochloric acid (HCl; A144-212), N-methylpyrrolidinone (NMP; BP1172-4, 1,1’ 
Carbonyldiimidazole (97%) (CDI, 530-62-1) and affinity pipettes fitted with porous 
microcolumns (991CUS01) were obtained from Thermo Scientific (Waltham, MA, USA). 
Tween20 (Cat. No. P7949), trifluoracetic acid (TFA, 299537), sinapic acid (85429-5G), sodium 
chloride (S7653), HEPES (H3375), ethanolamine (ETA; 398136), albumin from bovine serum 
(BSA; A7906) and lysozyme from chicken egg white (L7651) were obtained from Sigma 
Aldrich (St. Louis, MO, USA). Acetone (Cat. No. 0000017150) was obtained from Avantor 
Performance Materials (Center Valley, PA, USA).  
2.2. Human samples  
A small set of 82 human Na2EDTA plasma samples was used for the method 
development and validation. These samples were received from the National University of 
Singapore, with signed informed consent, without any identifiers, and labeled only with a 
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barcode. The samples were centrifuged for 5 min at 3,000 rpm, and then aliquoted into 96-well 
microplates (V = 90 µL) and stored at -80°C. Prior to analysis, the samples were thawed and 
diluted by adding 3 µL of each sample aliquot into 117 µL PBS, 0.1%Tween (40x dilution). 
2.3. Antibody immobilization 
Activation of the microcolumns in the affinity pipettes was executed using a Multimek 96 
channel pipettor (Beckman Coulter, Brea, CA). The affinity pipettes were first rinsed with 200 
mM HCl (2 x 20 aspiration/dispense cycles, 100 µL volume), followed by acetone rinse (20 
aspiration/dispense cycles, 100 µL). The pipettes were then immersed into a microplate 
containing 100 mg/mL 1,1’ Carbonyldiimidazole (in methyl-1pyrrolidone-2 (NMP)), and 450 
cycles of 100 μL aspirations and dispenses through each affinity pipette were performed. Two 
rinses with NMP (10 cycles each, 150 μL) followed. The affinity pipettes were then immediately 
immersed into the wells of a 96-microwell microplate which contained the antibody mixture: 
0.32 µg anti-apoC-I; 2.25 µg anti-apoC-II; 2.5 µg anti-apoC-II; and 0.40 µg anti-Lys; dissolved 
into 50 µL of 10 mM MES buffer (these amounts of antibodies were determined empirically to 
yield comparable signals of the targeted proteins in the mass spectra; they differed because of the 
unique affinities of each antibody toward the targeted protein) . A total of 750 cycles of 
aspirations and dispenses of the antibody mixture were performed, followed by rinses with 
ethanolamine (50 cycles, 100 µL) and twice with HBS-N buffer (100 cycles, 100 µL). The 
derivatization process took 2 hours, for 96 pipettes. The antibody-derivatized pipettes were 
stored at +4°C until used (storage was good for > 6 months).  
2.4. Sample preparation 
For the standard curves, a mixture containing equal mass of the three purified human 
apolipoproteins was prepared to a final concentration of 10 mg/L (total apolipoproteins). The 
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protein standards mixture was then serially diluted to 5 mg/L, 2.5 mg/L, 1.25 mg/L, 0.625 mg/L, 
0.313 mg/L and 0.156 mg/L, in PBS buffer containing 3 g/L BSA. Analytical samples were 
prepared by combining 30 µL of the 40x diluted plasma (or the protein standards mixture) with 
30 µL of a 0.1 mg/mL solution of lysozyme, and 60 µL PBS with 0.1% Tween, yielding a total of 
120 µL analytical sample volume. Standards and analytical samples were run simultaneously on 
the same multi-channel robotic pipettor. 
2.5. Assay execution 
The antibody-derivatized affinity pipettes were mounted onto the head of the Multimek 
96-channel pipettor. The MSIA started with an assay buffer rinse (PBS, 0.1% Tween, 10 
aspirations and dispense cycles, 100 µL each). Next, the affinity pipettes were immersed into a 
microplate containing the analytical samples and 250 aspirations and dispense cycles were 
performed (100 µL each) allowing for affinity capture of all the proteins from the samples. The 
affinity pipettes were then rinsed with assay buffer (100 cycles, 100 µL volumes), and twice with 
water (10 cycles and 20 cycles, 100 µL) to remove non-specifically bound proteins from the 
microcolumns. For elution of the captured proteins, 6 µL aliquots of MALDI matrix (15 g/L 
sinapic acid in aqueous solution containing 33 % (v/v) ACN, and 0.4 % (v/v) TFA) were 
aspirated into each affinity pipette, and after a 10 second delay (to allow for the dissociation of 
the proteins from the capturing antibodies), the eluates were dispensed directly onto a 96-well 
formatted MALDI target. Following drying, linear mass spectra were acquired from each sample 
spot using Bruker’s Ultraflex III MALDI-TOF instrument (Bruker, Billerica, MA). The 
instrument was operated in positive ion mode, in the mass range from 5 to 30 kDa, with 200 ns 
delay, 20.00 kV and 18.45 kV ion source voltages, and signal suppression up to 500 Da. 
Approximately 5,000 laser-shot mass spectra were saved for each standard and sample. 
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2.6. Data analysis 
Mass spectra were internally calibrated using the protein calibration standard I, and 
further processed with Flex Analysis 3.0 software (Bruker Daltonics). All peaks representing 
apolipoproteins and their proteoforms, along with the lysozyme IRS peak, were integrated 
baseline-to-baseline using Zebra 1.0 software (Intrinsic Bioprobes Inc), and the obtained peak 
area values were tabulated in a spreadsheet. To distinguish between noise and low intensity 
signals, the peak areas were corrected individually with baseline noise-bin signals (10 Da wide), 
picked from regions in the mass spectra in close proximity to the integrated protein signals. The 
corrected apolipoprotein peak areas were then normalized (divided) with the IRS peak area. For 
the plasma samples, the normalized peak areas for each apolipoprotein and its proteoforms were 
summed up, and the total apolipoprotein C-I, C-II, and C-III concentrations was determined 
using the corresponding apo C-I, C-II and C-III standard curves. The concentrations of the 
individual proteoforms were determined based on their percentage of the total concentrations for 
each individual apoC protein.  
3. Results  
3.1. Multiplex MSIA of human apolipoproteins C-I, C-II and C-III and their proteoforms 
Multiplex assays have great allure in proteomics [38]. Currently, only a limited number 
of MS-based methodologies are amenable of multiplex protein analyses, including MSIA [39] 
and selected peptide-based proteomics approaches [40-42]. In this work we demonstrate a 
multiplex MSIA for the apoC-I, apoC-II, apoC-III and their proteoforms.   
Presented in Fig. 1 is an example of mass spectra resulting from the multiplex apoCs 
MSIA. Signals from native apoC-I (MW 6,630 Da), apoC-II (MW 8,915 Da), apoC-III (MW 
8,765 Da) and the IRS, lysozyme (MW 14,305 Da), were clearly identified in all samples, along 
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with several proteoforms. To identify the proteoforms, two internal calibrations were performed 
– first one using protein calibration standard I (Bruker, Billerica, MA), and second, using the IRS 
in the spectrum. Masses were calibrated up to 0.001 Da in m/z, in order to achieve accurate mass 
assignment for the peaks in the mass spectra. Using this approach, and accounting for the 
selectivity of the apoCs antibodies, we were able to identify several proteoforms, as listed in 
Table 1.  The table shows the theoretical and observed mz/values of the proteoforms, their 
distribution (relative percent abundance, as calculated from the total for each apoC), and the 
frequency of the proteoforms in the cohort. Most of the proteoforms were detected in all 
samples, with the exception of the low abundance fucosylated apoC-III proteoforms.  
For apoC-I, beside the native full-length form, one additional proteoform was detected 
and identified as a sequence lacking two N-terminal amino acids (des-TP apoC-I; MW 6,432 
Da). This proteoform was identified in all samples and is a well-known product of dipeptidyl-
peptidase IV (DPP-4) enzymatic cleavage [43, 44].  
For apoC-II, a proteoform lacking six N-terminal amino acids (des-TQQPQQ apoC-II; 
MW 8,204 Da) was identified in all samples. This proteoform is termed mature apoC-II [45], and 
it is of low abundance (accounting for <10 % of the total apoC-II). The full-length apoC-II, also 
called pro-apoC-II, represents ~ 90% of the total apoC-II.  
For apoC-III, we detected a total of 12 proteoforms, including the full-length native 
apoC-III and numerous glycosylated proteoforms. ApoC-III is highly heterogeneous protein 
because of the extensive protein glycosylation [34]. The most abundant proteoform is apoC-III 
containing one N-acetyl neuraminic acid (NeuAc; sialic acid) attached to a glycan core of one 
galactose (Gal) and one N-acetylgalactosamine (GalNAc): apoC-III-(Gal)1(GalNAc)1(NeuAc)1. 
This proteoform is commonly referred to as apoC-III1 (one sialic acid) in the literature, with the 
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other two most abundant forms being apoC-III-(Gal)1(GalNAc)1 and apoC-III-
(Gal)1(GalNAc)1(NeuAc)2, commonly referred to as apoC-III0 (no sialic acid) and apoCIII2 (two 
sialic acids), respectively [32]. 
3.2 Quantitative MSIA analysis of apoC-I, apoC-II, apoC-III and their proteoforms  
Quantification of the apoCs in this multiplex MSIA was achieved through the generation 
of three standard curves (one each for apoC-I, apoC-II and apoC-III), utilizing the corresponding 
protein standards. Because all three apolipoproteins were analyzed in the same assay, a single, 
exogenous protein (chicken-egg lysozyme) was added in the analytical samples as an internal 
reference standard (IRS) for quantification. The choice of IRS was critical step in the method 
development, because it had to satisfy all the necessary requirements in these “fit-for-purpose” 
approaches [46]. Chicken-egg lysozyme, a non-human protein, was a good choice for an IRS 
because it is not present in human plasma (therefore, avoiding cross-reactivity), and its signal in 
the mass spectrum (at m/z = 14,305 Da) is in close proximity to the signals from the apoCs (thus 
ensuring similar MS instrument settings use). The IRS was added in constant concentration in all 
analytical samples (standards and plasma), and produced a constant signal in the mass spectra.  
The physiological concentrations of the three apoCs is in the mg/L range, with apoC-III 
having the highest range (80 – 150 mg/L), and  apoC-I and apoC-II exhibiting similar 
concentration ranges (40 – 60 mg/L and 30 – 50 mg/L, respectively). The three standard curves, 
therefore were generated with an identical concentration range (0.156 – 5 mg/L) that was 
sufficient for quantitation of all the proteoforms (the plasma samples were diluted 40-fold). 
Examples of the standard curves, along with the corresponding mass spectra are presented in Fig. 
2. The response for all standard curves is linear across the entire range (r2 = 0.9988, SEE = 
0.0928 for apoC-I; r
2 
= 0.9940, SEE = 0.0262 for apoC-II; and r
2 
= 0.9996, SEE = 0.1605 for 
11 
 
apoC-III). A control sample with known apoC-I, apoC-II and apoC-III concentrations (1 mg/L 
each) was analyzed in triplicate each day in order to assess the inter-day variability, and 
presented CVs of 8.82 % (apoC-I), 7.88 % (apoC-II) and 10.1 % (apoC-III).Linearity of the 
assay was evaluated by analyzing several admixtures of plasma samples with various 
concentrations of the apoCs, yielding a recovery of 89-124%. 
Using these standard curves we determined the concentrations of all apoCs and their 
proteoforms in the 82 human plasma samples (Fig. 3). We first determined the protein/lysozyme 
peak areas ratios for each proteoform, summed up the ratios of all proteoforms for an individual 
protein, determined the total individual protein concentration using the corresponding standard 
curve, and then determined the concentration of each proteoform based on its percentage of the 
total specific apoC concentration. This approach worked especially well for those proteoforms 
whose proteoform/lysozyme peak ratios were below those of the standard curve. The total 
concentrations were in the range of 13.8 to 148 mg/L for apoC-I (mean = 59.2 mg/L), 30.2 to 
161 mg/L for apoC-II (77.8 mg/L) and 20.4 to 188 mg/L for apoC-III (76.7 mg/L), which is 
within the range of normal concentrations as determined by conventional immunoassays. The 
concentration ranges for the individual proteoforms are shown in Fig. 3.  
4. Discussion 
Delineating protein heterogeneity is an important undertaking because of its implications 
in physiological and pathological processes. The MSIA methodology can unambiguously 
distinguish between different proteoforms in a single assay. The approach is time efficient (~40 
min) and high-throughput, allowing us to study the range of apoCs proteoforms from a small 
cohort of 82 human plasma samples in a single run on the automated 96-channel pipettor.  
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The apoC-I des-TP proteoform, a product of a DPP-4 enzymatic cleavage, was identified 
in all samples. Analyzing this proteoform is significant for several reasons. First, the des-TP 
apoC-I proteoform accounts for approximately a quarter of the total apoC-I in normal plasma 
(Table 1), making a significant contribution to the overall apoC-I concentration. Second, this 
proteoforms could potentially be used as a marker of DPP-4 inhibitor drugs activity. DPP-4 
inhibitor drugs, such as vildagliptin, sitagliptin and sexagliptin,  are prescribed for the treatment 
of type 2 diabetes (T2D) for controlling the HbA1C levels and preservation of the progressive 
loss of insulin-secreting capacity [47, 48]. DPP-4 cleaved apoC-I can therefore be a useful 
marker for the effect of DPP-4 inhibitor drugs and monitoring of therapy.  
ApoC-II is a relatively homogenous protein exhibiting just two proteoforms: pro-apoC-II 
(the dominant proteoform), and mature apoC-II - a proteoform resulting from the removal of an 
N-terminal hexapeptide (TQQPQQ). ApoC-II has been primarily associated with activation of 
the lipoprotein lipase (LPL), and promoting triglyceride hydrolysis in lipid particles [24]. 
Deficiency of apoC-II was shown to cause hypertriglyceridemia, which can be reversed by 
infusion with normal plasma or synthetic apoC-II in affected individuals [49]. The MSIA 
approach measures both proteoforms - the pro- and mature apoC-II, and can be used for 
monitoring and predicting the kinetics of maturation of this apolipoprotein in vivo.  
ApoC-III heterogeneity is a result of its glycosylation and presence of O-linked glycan 
motifs w/o and w/ one and/or two sialic acid molecules. These glycosylated forms (termed apoC-
III0, apoC-III1 and apoC-III2) derive from glycosylation on threonine 74 (T74) in the amino acid 
sequence, and account for ~ 90 % of the total apoC-III concentration (Table 1). Our results 
indicate that apoC-III exhibits additional proteoforms: the low abundance C-terminal alanine 
cleaved proteoforms (present in majority of the samples, at 1 to 5 %), and also glycosylated 
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proteoforms containing fucose in the glycan motif. The presence of fucosylated apoC-III has 
initially been detected by Balog et al., in relation to Schistosoma mansoni infection [50]. 
Nicolardi et al. confirmed the presence of fucosylated apoC-III proteoforms in their work [33], 
and went a step further in analyzing these glycan structures using MALDI-FTICR MS [51]. 
Their approach, however, is time consuming, and requires sample pretreatment using magnetic 
beads-based solid-phase extraction prior to MALDI and ESI-FTICR MS analysis. In our work 
we were able to apply the MSIA approach and detect these low abundance apoC-III proteoforms 
in a single run alongside the other apoCs, therefore significantly reducing the time and cost of 
the analysis. The concentrations of the fucosylated apoC-III proteoforms were determined to be 
in the very low mg/L range (Fig. 3). With the exception of apoC-III-(Gal)2(GalNAc)2(Fuc)3, they 
were detected in less than 20 % of samples. Finally, the distribution of the apoC-III proteoforms 
was noticeably different among the samples, even in samples with similar total apoC-III 
concentrations. This was especially evident for the fucosylated proteoforms of apoC-III, 
suggesting that fucosylation follows different pathways. Additional studies are needed in order to 
better understand these differences in the context of the physiological significance.  Gaining an 
insight into the structural heterogeneity of apoC-III will certainly contribute to new findings and 
correlations, especially when assessed together with apoC-I and apoC-II, as done here with the 
multiplex MSIA.  
5. Conclusion 
The multiplex apoCs assay is based on the mass spectrometric immunoassay (MSIA) 
methodology. The assay’s two step approach is similar to that of well-established enzymatic 
immunoassays, with the secondary step of MALDI-MS detection an enabling factor in 
differentiating between multiple proteoforms. The quantification aspect further strengthens the 
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methodology because the concentration of each proteoforms can be determined individually. The 
multiplex quantitative MSIA is a unique and high-throughput method for measuring the three 
apoproteins C and their proteoforms. The ability to detect and quantify all proteoforms in a 
single assay represents a significant step forward toward better understanding of their 
physiological roles in health and disease. 
 
Acknowledgements 
The authors would like to acknowledge Dr. Tai E Shyong and Dr. Kao Shih Ling from National 
University Hospital, Singapore for providing us with the human plasma samples used in this 
analysis. This work was supported in part by Award Numbers R01DK082542 and 
R24DK090958 from the National Institute of Diabetes and Digestive and Kidney Diseases. The 
content is solely the responsibility of the authors and does not necessarily represent the official 
views of the National Institutes of Health. 
 
  
15 
 
Table 1. ApoC-I, apoC-II and apoC-III proteoforms, with their relative percent abundance 
(RPA) and frequency in a cohort of 82 human EDTA-plasma samples 
 
 
  
Proteoforms Theoretical 
m/z value 
Observed 
m/z value 
RPA (%) 
Mean (range) 
Frequency 
(%) 
des-TP apoC-I  6432.344 6432.104 21.3 (13.6 – 27.0) 100 
apoC-I native 6630.565 6630.572 78.7 (72.9 – 86.4) 100 
des-TQQPQQ apoC-II  8204.162 8205.290 8.51 (4.09 – 13.7) 100 
apoC-II native 8914.906 8915.760 91.5 (86.3 – 95.9) 100 
apoC-III native  8764.652 8764.587 6.85 (1.06 – 19.0) 100 
apoC-III-(Gal)1(GalNAc)1 9135.800 9137.925 29.9 (25.4 – 36.8) 100 
des-A apoC-III-(Gal)1(GalNAc)1(NeuAc)1  9350.171 9351.781 1.17 (0.336 – 3.65) 93.9 
apoC-III-(Gal)1(GalNAc)1(NeuAc)1 9422.249 9422.562 40.6 (29.1 – 48.3) 100 
des-A apoC-III-(Gal)1(GalNAc)1(NeuAc)2  9641.429 9642.267 5.96 (4.32 – 9.26) 100 
apoC-III-(Gal)1(GalNAc)1(NeuAc)2 9712.507 9713.492 12.1 (6.63 – 19.4) 100 
apoC-III-(Gal)2(GalNAc)2(Fuc)3 9933.768 9933.941 2.61 (0.477 – 6.83) 100 
apoC-III-(Gal)3(GalNAc)3(Fuc)2 10152.961 10153.559 0.949 (0.241 – 1.42) 12.2 
apoC-III-(Gal)4(GalNAc)2(Fuc)3 10258.056 10259.700 1.74 (0.139 – 3.78) 20.7 
apoC-III-(Gal)2(GalNAc)4(Fuc)3 10340.158 10341.098 1.40 (0.837 – 2.00) 17.1 
apoC-III-(Gal)3(GalNAc)3(Fuc)4 10445.869 10446.206 0.507 (0.209 – 0.771) 15.9 
apoC-III-(Gal)5(GalNAc)3(Fuc)4 10769.541 10770.404 0.924 (0.593 – 1.53) 12.2 
Gal – Galactose; GalNAc - N-acetylgalactosamine; NeuAc - N-acetyl neuraminic acid (sialic acid); Fuc – Fucose  
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Figures legends: 
 
Figure 1: Mass spectra resulting from multiplex MSIA of apoC-I, apoC-II and apoC-III utilizing 
lysozyme as an IRS. Labeled on the mass spectra are the major C apolipoprotein proteoforms. 
The inlets represent mass spectra obtained from samples where the specific proteoforms were 
more prominent. 
 
Figure 2: Quantitative apoC-I, apoC-II and apoC-III mass spectrometric immunoassay (MSIA). 
a) Representative  MSIA mass spectra for the six standard apoCs samples containing lysozyme 
as an IRS; b) Representative standard curves generated with the multiplex apoCs MSIA, with an 
r
2
= 0.9988 and SEE = 0.0928 for apoC-I; r
2 
= 0.9940 and SEE = 0.0262 for apoC-II; and r
2 
= 
0.9996 and SEE = 0.1605 for apoC-III. 
 
Figure 3: Individual concentrations of apolipoprotein C-I, C-II and C-III and their proteoforms 
in a cohort of 82 human EDTA-plasma samples. Box - 25-75
th
 percentile; Solid line – median 
concentration; Short dash line – mean concentration; Error bars – 10th and 90th percentile; 
Symbols – outlying points.  
 
20 
 
 
Figure 1 
 
 
21 
 
 
Figure 2.a) 
22 
 
 
Figure 2.b) 
 
23 
 
 
Figure 3 
